Uniplan Investment Counsel Inc. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 0.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 613,756 shares of the biopharmaceutical company’s stock after acquiring an additional 1,897 shares during the period. Uniplan Investment Counsel Inc.’s holdings in Pfizer were worth $21,911,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. Shine Investment Advisory Services Inc. acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $103,000. Herndon Capital Management LLC acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $120,000. Lipe & Dalton grew its position in shares of Pfizer by 6.9% during the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 300 shares during the period. Finally, Legacy Advisors LLC acquired a new position in Pfizer during the third quarter valued at approximately $164,000. Institutional investors own 70.12% of the company’s stock.
Pfizer Inc. (NYSE PFE) opened at $36.26 on Friday. The firm has a market cap of $216,140.00, a P/E ratio of 20.72, a PEG ratio of 2.02 and a beta of 0.94. Pfizer Inc. has a 1-year low of $31.67 and a 1-year high of $39.43. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The company had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 26.86%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.47 earnings per share. sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.75%. The ex-dividend date of this dividend is Thursday, February 1st. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is 77.71%.
Pfizer announced that its Board of Directors has approved a share buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.
A number of research analysts recently issued reports on PFE shares. BMO Capital Markets set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, October 31st. JPMorgan Chase & Co. set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, November 1st. UBS Group set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, November 1st. Deutsche Bank set a $38.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Wednesday, December 6th. Finally, Vetr upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price objective for the company in a report on Thursday, November 23rd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $39.45.
In other news, insider Alexander R. Mackenzie sold 6,750 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the sale, the insider now owns 103,458 shares of the company’s stock, valued at $3,827,946. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of the business’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.07, for a total transaction of $296,560.00. Following the completion of the sale, the executive vice president now directly owns 46,963 shares in the company, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. 0.06% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Uniplan Investment Counsel Inc. Has $21.91 Million Stake in Pfizer Inc. (PFE)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/24/uniplan-investment-counsel-inc-has-21-91-million-stake-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.